D. Boral Capital Reiterates “Buy” Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective indicates a potential upside of 274.61% from the stock’s current price.

A number of other brokerages have also recently commented on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Rodman & Renshaw assumed coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 3.9 %

Shares of NASDAQ OMER traded up $0.36 during trading hours on Thursday, reaching $9.61. 724,692 shares of the stock traded hands, compared to its average volume of 507,703. The company has a market capitalization of $556.90 million, a P/E ratio of -4.16 and a beta of 1.98. The company’s 50-day simple moving average is $9.25 and its two-hundred day simple moving average is $6.69. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60.

Hedge Funds Weigh In On Omeros

Institutional investors have recently bought and sold shares of the stock. Truvestments Capital LLC raised its holdings in Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new stake in Omeros during the fourth quarter worth about $46,000. BNP Paribas Financial Markets increased its stake in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management lifted its holdings in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.